Fexinidazole Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 600 mg
Reference Brands: Generic formulations marketed under different names
Category:
Critical Care
Fexinidazole is available in Tablets
and strengths such as 600 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fexinidazole is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fexinidazole can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fexinidazole is an oral medication used for the treatment of African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense. It is effective against both early and late stages of the disease, including cases involving the central nervous system. Fexinidazole represents a major advancement in the treatment of sleeping sickness, being the first new drug candidate for advanced-stage disease in over thirty years.
Clinical trials in Africa have demonstrated that fexinidazole is approximately 91% effective in treating sleeping sickness. While it may be slightly less effective than the combination therapy of nifurtimox with eflornithine in severe late-stage cases, its key advantage is oral administration, eliminating the need for complex intravenous treatment regimens. This makes therapy more accessible and practical, especially in remote or resource-limited settings where sleeping sickness is endemic. By simplifying treatment while maintaining high efficacy, fexinidazole has become a breakthrough option for improving outcomes and reducing the burden of care in affected populations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing